| Description |
1 online resource |
| Contents |
FOREWORD ; PREFACE ; List of Contributors ; Section I: General Topics ; Neurobiology and Psycho-Social Basis for Addiction and Related Disorders ; KEY LEARNING POINTS; NEUROBIOLOGY OF ADDICTION AND REWARD PATHWAYS; PSYCHOSOCIAL FACTORS; ADVERSE CHILDHOOD EXPERIENCES (ACE); CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Urine Drug Screening (UDS) in the Management of Substance Use Disorders ; KEY LEARNING POINTS; CLINICAL VIGNETTE; DIAGNOSTIC CONSIDERATION; REASONS FOR OBTAINING AN UDS; URINE DRUG SCREENS; Types of Urine Drug Tests; Urine Drug Test as a Follow-up Tool |
|
Urine Sample CollectionChain of Custody; Medication Interfering with UDS; SPECIAL CONSIDERATIONS; Opiate/Opioid Metabolism; Benzodiazepines; Untested Substances; Altered Pharmacokinetic and Pharmacodynamic Parameters; SUMMARY; PATIENT INFORMATION SHEET -- URINE DRUG SCREENS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Genetics of Addiction ; KEY LEARNING POINTS; GENETICS OF ADDICTION; SUMMARY; PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Dual Diagnosis ; KEY LEARNING POINTS; CLINICAL VIGNETTE; BACKGROUND; DIAGNOSTIC CONSIDERATIONS |
|
TREATMENT CONSIDERATIONSTREATMENT OUTCOMES; SUMMARY; DUAL DIAGNOSIS -- PATIENT INFORMATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Pharmacologic Treatment for Psychiatric Disorders Associated with Substance Use Disorders: An Overview ; KEY LEARNING POINTS; INTRODUCTION; Benzodiazepines (Table 1); Antidepressants; Serotonin Syndrome; Syndrome Presentation; Treatment; SSRI Withdrawal Phenomenon; Atypical/Typical Antipsychotics; Dosing; Monitoring; Additional Monitoring Recommended; Other Side Effects; Extrapyramidal Side Effects (EPSE); Treatment of Early -- EPSE |
|
Dystonias and PseudoparkinsonismAkathisia; Treatment of Tardive Dyskinesia; Neuroleptic Malignancy Syndrome (NMS); Mood Stabilizers; Anticonvulsants; Management of Insomnia; SUMMARY; PATIENT INFORMATION -- MEDICATIONS FOR SUBSTANCE USE DISORDERS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Motivational Interviewing ; KEY LEARNING POINTS; BACKGROUND; PROCESS; MOTIVATION ENHANCEMENT; THE STAGES OF CHANGE; SUMMARY; MOTIVATIONAL INTERVIEW-PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Section II: Substance-Related Addiction Disorders (Alphabetical) |
|
Alcohol Use Disorders KEY POINTS; CLINICAL VIGNETTE; INTRODUCTION; Epidemiology; Etiology; Diagnosis; Non-Pharmacologic Interventions; Pathophysiology of Alcohol Use Disorders (AUD); PHARMACOTHERAPY FOR ALCOHOL USE DISORDERS (AUD); Management of Outpatient Alcohol Withdrawal; FDA Approved Medications for Alcohol Use Disorder [26]; Disulfiram (Antabuse®) [19, 21, 27]; Naltrexone (Revia® (PO), Vivitrol® (IM)); Acamprosate (Campral®) [21, 28, 30]; Combination Therapy; Non-FDA Approved Pharmacotherapies for AD; SUMMARY; CLINICAL VIGNETTE RESOLUTION; PROVIDER RESOURCES |
| Bibliography |
Includes bibliographical references and index |
| Subject |
Substance abuse -- Diagnosis.
|
|
Substance abuse -- Treatment.
|
|
Compulsive behavior.
|
|
Compulsive Behavior
|
|
Behavior, Addictive
|
|
addiction.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Compulsive behavior
|
|
Substance abuse -- Diagnosis
|
|
Substance abuse -- Treatment
|
| Form |
Electronic book
|
| Author |
Bhatia, Subhash C., editor
|
|
Petty, Frederick, editor
|
|
Gabel, Teri, editor
|
| ISBN |
1681083434 |
|
9781681083438 |
|
